ALTANA TO LEAD ONCOLOGY PRODUCTS INTO PHASE I TRIALS

Altana has announced that it expects to lead its oncology projects into clinical Phase I trials in the next two years. In oncology, Altana focuses on the development of antimitotic cancer agents to substitute for current taxane-based chemotherapy.

The company also wants to bring the next generation of HDAC (histone deacetylase) inhibitors, which hems growth in a wide range of tumor models. The objective of this oncology research is to find compounds that will allow for longterm treatment to turn cancer into a chronic controlled disease.